Humana (NYSE:HUM) Given New $285.00 Price Target at Morgan Stanley

Humana (NYSE:HUM) had its price target decreased by Morgan Stanley from $301.00 to $285.00 in a research report sent to investors on Wednesday morning,Benzinga reports. Morgan Stanley currently has an equal weight rating on the insurance provider’s stock.

HUM has been the subject of several other reports. Barclays boosted their price objective on shares of Humana from $253.00 to $255.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 22nd. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and boosted their price objective for the company from $247.00 to $308.00 in a research report on Wednesday, November 6th. Wells Fargo & Company lowered their price objective on shares of Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. TD Cowen boosted their price objective on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Finally, Piper Sandler boosted their price objective on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Nineteen equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $292.26.

Humana Stock Up 1.0 %

Shares of HUM opened at $259.93 on Wednesday. Humana has a 12 month low of $213.31 and a 12 month high of $406.46. The firm’s 50 day moving average is $273.00 and its 200-day moving average is $295.72. The stock has a market capitalization of $31.30 billion, a PE ratio of 23.02, a P/E/G ratio of 2.11 and a beta of 0.56. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last announced its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.18% and a return on equity of 13.20%. Equities research analysts forecast that Humana will post 16.11 EPS for the current year.

Insider Buying and Selling

In related news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.32% of the stock is currently owned by insiders.

Institutional Trading of Humana

Several institutional investors have recently modified their holdings of HUM. Creative Financial Designs Inc. ADV grew its stake in shares of Humana by 244.0% in the third quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 61 shares during the last quarter. FPC Investment Advisory Inc. acquired a new position in Humana in the fourth quarter valued at $27,000. Centricity Wealth Management LLC acquired a new position in Humana in the fourth quarter valued at $30,000. Ashton Thomas Securities LLC acquired a new position in Humana in the third quarter valued at $31,000. Finally, Your Advocates Ltd. LLP lifted its holdings in Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock valued at $32,000 after buying an additional 45 shares during the period. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.